Immunotherapy biomarkers 2016: overcoming the barriers

James L Gulley¹, Jay A Berzofsky², Marcus O Butler³, Alessandra Cesano⁴, Bernard A Fox⁵, Sacha Gnjatic⁶, Sylvia Janetzki⁷, Shyam Kalavar⁸, Vaios Karanikas⁹, Samir N Khleif¹⁰, Ilan Kirsch¹¹, Peter P Lee¹², Cristina Maccalli¹³, Holden Maecker¹⁴, Jeffrey Schlom¹⁵, Barbara Seliger¹⁶, Janet Siebert¹⁷, David F Stroncek¹⁸, Magdalena Thurin¹⁹, Jianda Yuan²⁰, Lisa H Butterfield²¹

Affiliations

¹ Genitourinary Malignancies Branch, Center for Cancer Research, NCI, 10 Center Dr., 13 N240, Bethesda, MD, 20892, USA.
² Vaccine Branch, Center for Cancer Research, 41 Medlars Dr, Bldg 41 Rm D702D, Bethesda, MD, 20892, USA.
³ Princess Margaret Cancer Center/Ontario Cancer Institute, RM 9-622, 610 University Ave, Toronto, ON, Canada.
⁴ NanoString, Inc., 500 Fairview Avenue North, Seattle, WA, 98109, USA.
⁵ Earle A. Chiles Research Institute, Providence Cancer Center, 4805 NE Glisan Street, Portland, OR, 97213, USA.
⁶ Department of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, S5-105, 1470 Madison Avenue, Box 1128, New York, NY, 10029, USA.
⁷ ZellNet Consulting, Inc., 555 North Avenue, Fort Lee, NJ, 07024, USA.
⁸ Center for Devices and Radiological Health, U.S. Food and Drug Administration, 1401 Rockville Pike, Rockville, MD, 20852, USA.
⁹ Roche Innovation Center Zurich, Wagistrasse 18, Schlieren, Switzerland.
¹⁰ Georgia Cancer Center, Augusta University, 1120 15th Street, CN-2101A, Augusta, GA, 30912, USA.
¹¹ Adaptive Biotechnologies, Inc., 1551 Eastlake Ave. E., Seattle, WA, 98102, USA.
¹² Department of Immuno-oncology, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA.
¹³ Department of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar.
¹⁴ Stanford University Medical Center, 299 Campus Drive, Stanford, CA, 94303, USA.
¹⁵ National Cancer Institute, National Institutes of Health, 10 Center Drive, Bldg. 10, Room 8B09, Bethesda, MD, 20892, USA.
¹⁶ Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, Halle, Germany.
¹⁷ CytoAnalytics, 3500 South Albion Street, Cherry Hills Village, CO, 80113, USA.
¹⁸ Department of Transfusion Medicine, National Institutes of Health, 10 Center Drive, Building 10, Room 3C720, Bethesda, MD, 20892, USA.
¹⁹ National Cancer Institute, Cancer Diagnosis Program, DCTD, National Institutes of Health, 9609 Medical Center Drive, Bethesda, 20892, MD, USA.
²⁰ Early Clinical Oncology Development, Merck Research Laboratories, Rahway, NJ, 07065, USA.
²¹ Department of Medicine, Surgery and Immunology, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA. butterfieldl@upmc.edu.

PMID: 28653584
PMCID: PMC5359902
DOI: 10.1186/s40425-017-0225-6

Immunotherapy biomarkers 2016: overcoming the barriers

James L Gulley et al. J Immunother Cancer. 2017.

. 2017 Mar 21;5(1):29.

doi: 10.1186/s40425-017-0225-6.

Authors

Affiliations

¹ Genitourinary Malignancies Branch, Center for Cancer Research, NCI, 10 Center Dr., 13 N240, Bethesda, MD, 20892, USA.
² Vaccine Branch, Center for Cancer Research, 41 Medlars Dr, Bldg 41 Rm D702D, Bethesda, MD, 20892, USA.
³ Princess Margaret Cancer Center/Ontario Cancer Institute, RM 9-622, 610 University Ave, Toronto, ON, Canada.
⁴ NanoString, Inc., 500 Fairview Avenue North, Seattle, WA, 98109, USA.
⁵ Earle A. Chiles Research Institute, Providence Cancer Center, 4805 NE Glisan Street, Portland, OR, 97213, USA.
⁶ Department of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, S5-105, 1470 Madison Avenue, Box 1128, New York, NY, 10029, USA.
⁷ ZellNet Consulting, Inc., 555 North Avenue, Fort Lee, NJ, 07024, USA.
⁸ Center for Devices and Radiological Health, U.S. Food and Drug Administration, 1401 Rockville Pike, Rockville, MD, 20852, USA.
⁹ Roche Innovation Center Zurich, Wagistrasse 18, Schlieren, Switzerland.
¹⁰ Georgia Cancer Center, Augusta University, 1120 15th Street, CN-2101A, Augusta, GA, 30912, USA.
¹¹ Adaptive Biotechnologies, Inc., 1551 Eastlake Ave. E., Seattle, WA, 98102, USA.
¹² Department of Immuno-oncology, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA.
¹³ Department of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar.
¹⁴ Stanford University Medical Center, 299 Campus Drive, Stanford, CA, 94303, USA.
¹⁵ National Cancer Institute, National Institutes of Health, 10 Center Drive, Bldg. 10, Room 8B09, Bethesda, MD, 20892, USA.
¹⁶ Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, Halle, Germany.
¹⁷ CytoAnalytics, 3500 South Albion Street, Cherry Hills Village, CO, 80113, USA.
¹⁸ Department of Transfusion Medicine, National Institutes of Health, 10 Center Drive, Building 10, Room 3C720, Bethesda, MD, 20892, USA.
¹⁹ National Cancer Institute, Cancer Diagnosis Program, DCTD, National Institutes of Health, 9609 Medical Center Drive, Bethesda, 20892, MD, USA.
²⁰ Early Clinical Oncology Development, Merck Research Laboratories, Rahway, NJ, 07065, USA.
²¹ Department of Medicine, Surgery and Immunology, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA. butterfieldl@upmc.edu.

PMID: 28653584
PMCID: PMC5359902
DOI: 10.1186/s40425-017-0225-6

Abstract

This report summarizes the symposium, 'Immunotherapy Biomarkers 2016: Overcoming the Barriers', which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cosponsored by the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI), focused on emerging immunotherapy biomarkers, new technologies, current hurdles to further progress, and recommendations for advancing the field of biomarker development.

Keywords: Baseline measures; Biomarkers; High throughput; Immune monitoring; Immunotherapy; Tumor microenvironment.

PubMed Disclaimer

References

1. Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation. J ImmunoTher Cancer. 2016;4(1):76. doi: 10.1186/s40425-016-0178-1. - DOI - PMC - PubMed
1. Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations. J ImmunoTher Cancer. 2016;4(1):77. doi: 10.1186/s40425-016-0179-0. - DOI - PMC - PubMed
1. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res. 2008;14(19):5967–76. doi: 10.1158/1078-0432.CCR-07-4535. - DOI - PMC - PubMed
1. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res. 2005;22(4):499–511. doi: 10.1007/s11095-005-2495-9. - DOI - PubMed
1. Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540–8. doi: 10.1158/1078-0432.CCR-13-3231. - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunotherapy biomarkers 2016: overcoming the barriers

Affiliations

Immunotherapy biomarkers 2016: overcoming the barriers

Authors

Affiliations

Abstract

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous